<code id='D8D7DAEE4C'></code><style id='D8D7DAEE4C'></style>
    • <acronym id='D8D7DAEE4C'></acronym>
      <center id='D8D7DAEE4C'><center id='D8D7DAEE4C'><tfoot id='D8D7DAEE4C'></tfoot></center><abbr id='D8D7DAEE4C'><dir id='D8D7DAEE4C'><tfoot id='D8D7DAEE4C'></tfoot><noframes id='D8D7DAEE4C'>

    • <optgroup id='D8D7DAEE4C'><strike id='D8D7DAEE4C'><sup id='D8D7DAEE4C'></sup></strike><code id='D8D7DAEE4C'></code></optgroup>
        1. <b id='D8D7DAEE4C'><label id='D8D7DAEE4C'><select id='D8D7DAEE4C'><dt id='D8D7DAEE4C'><span id='D8D7DAEE4C'></span></dt></select></label></b><u id='D8D7DAEE4C'></u>
          <i id='D8D7DAEE4C'><strike id='D8D7DAEE4C'><tt id='D8D7DAEE4C'><pre id='D8D7DAEE4C'></pre></tt></strike></i>

          Home / Wikipedia / Wikipedia

          Wikipedia


          Wikipedia

          author:hotspot    Page View:59
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In